Suppr超能文献

[深圳乙肝病毒基因型与前C区/核心启动子突变及抗病毒效果的关系]

[Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects].

作者信息

Yuan Jing, Zhou Bo-ping, Gong Zuo-jiong, Xu Liu-mei, Jiang Xiao-ling, Mizokami Masashi

机构信息

Shenzhen East Lake Hospital, Shenzhen 518020, China.

出版信息

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2006 Mar;20(1):30-2.

Abstract

BACKGROUND

To study the relationship between hepatitis B virus genotyping Shenzhen isolates and HBV precore/core promoter mutation and antiviral effects.

METHODS

The HBV genotyping of 165 patients with HBV was carried out with mAbs ELISA. HBV precore/core promoter mutation was detected with gene chip technology in 24 patients with CHB. The relationship between HBV genotyping and interferon, lamivudine effects was analyzed.

RESULTS

(1) Out of 165 cases, 106 (64.2%) of type B but 48 (29.1%) of type C were found. Type B accounted for 95.4% in group ASC, and type C for 64.7%in group LC (P<0.05). (2) Precore/core promoter mutation was found in 16 cases (10 of type B, and 6 of type C) out of 24 cases. Out of 16 cases, precore/core promoter mutation (nt1896, 1862) was found in 10 cases (9 cases of type B and 1 case of type C), while basal core promoter mutation (BCP mutation, nt1762,1764) was found in 6 cases (1 case of type B and 5 of type C). (3) Among 27 patients with CHB HBAg (+) treated with interferon, 11 cases of type B but 1 case of type C were tested to be fully responsive to interferon. Among 29 patients with CHB HBAg (+) treated with lamivudine, 15 cases of type B but 3 cases of type C were tested to be continuously responsive to lamivudine.

CONCLUSION

(1) HBV genotype popularity in Shenzhen area was classified as type B the first and type C the second. (2) Type C seems more apt to develop BCP mutation and cirrhosis, and to be less responsive to interferon or lamivudine.

摘要

背景

研究深圳地区乙型肝炎病毒基因分型与乙肝病毒前C区/核心启动子突变及抗病毒疗效之间的关系。

方法

采用单克隆抗体酶联免疫吸附试验(mAbs ELISA)对165例乙肝患者进行乙肝病毒基因分型。应用基因芯片技术检测24例慢性乙型肝炎(CHB)患者的乙肝病毒前C区/核心启动子突变情况。分析乙肝病毒基因分型与干扰素、拉米夫定疗效之间的关系。

结果

(1)165例患者中,发现B型106例(64.2%),C型48例(29.1%)。B型在无症状慢性乙肝(ASC)组中占95.4%,C型在肝硬化(LC)组中占64.7%(P<0.05)。(2)24例患者中,16例(B型10例,C型6例)检测到前C区/核心启动子突变。16例中,10例(B型9例,C型1例)检测到前C区/核心启动子突变(nt1896、1862),6例(B型1例,C型5例)检测到基本核心启动子突变(BCP突变,nt1762、1764)。(3)27例接受干扰素治疗的CHB HBAg(+)患者中,B型11例对干扰素完全应答,C型1例;29例接受拉米夫定治疗的CHB HBAg(+)患者中,B型15例对拉米夫定持续应答,C型3例。

结论

(1)深圳地区乙肝病毒基因型以B型为主,其次为C型。(2)C型似乎更易发生BCP突变和肝硬化,且对干扰素或拉米夫定的应答较差。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验